NewAmsterdam Pharma Company (NAMS) AI Stock Analysis

• Market Cap: $4.35B
• Dividend Yield: N/A
• Average Volume (3M): 943.85K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.32
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 68
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.61
• Shares Outstanding: 113,390,800
• 10 Day Avg. Volume: 851,250
• 30 Day Avg. Volume: 943,848
• PEG Ratio: -0.53
• Price to Book (P/B): 3.20
• Price to Sales (P/S): 53.22
• P/FCF Ratio: -15.23
• Enterprise Value/Market Cap: 0.62
• Enterprise Value/Revenue: 76.05
• Enterprise Value/Gross Profit: 76.05
• Enterprise Value/Ebitda: -9.30
• 1Y Price Target: $47.57
• Price Target Upside: 24.11% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9
• EPS Forecast (FY): -1.47
• Revenue Forecast (FY): $27.10M

• Rating: 58 Neutral
• Price Target: $36.00 ▼(-6.08% Downside)

The stock score is primarily influenced by the company's strong technical performance, indicating positive market momentum. However, financial performance is a concern due to ongoing operational losses and negative cash flows, typical of biotech firms in early stages. Valuation is challenging due to negative earnings, but the company's ability to raise capital provides some stability.

Positive Factors

Regulatory Milestone

EMA validation is a critical step towards commercialization in Europe, expanding market reach and enhancing competitive positioning in the cardiovascular treatment sector.

Clinical Trial Success

Successful trial results position NAMS as a leader in both cardiovascular and neurodegenerative disease treatment, potentially increasing market share and revenue.

Strategic Partnerships

The partnership with Menarini enhances distribution capabilities and operational efficiency, supporting long-term growth and market penetration.

Negative Factors

Profitability Challenges

Persistent operational losses due to high R&D costs can strain financial resources, delaying profitability and impacting long-term financial health.

Negative Cash Flow

Negative cash flow indicates ongoing cash burn, which may necessitate further capital raising, potentially diluting existing shareholders.

Volatile Revenue

Revenue volatility can complicate financial planning and investor confidence, impacting the company's ability to sustain long-term growth.

NewAmsterdam Pharma Company Business Overview & Revenue Model

Company Description

NewAmsterdam Pharma Company (NAMS) is a biopharmaceutical company focused on developing innovative therapies for metabolic diseases, particularly in the areas of dyslipidemia and cardiovascular conditions. The company is dedicated to advancing novel drug candidates that aim to improve patient outcomes and address unmet medical needs. NAMS operates primarily in the pharmaceutical sector, leveraging cutting-edge research and development to create and commercialize its core products, which include therapies designed to manage cholesterol levels and reduce cardiovascular risk.

How the Company Makes Money

NewAmsterdam Pharma generates revenue primarily through the commercialization of its pharmaceutical products, which are sold to healthcare providers, hospitals, and pharmacies. The company may also engage in strategic partnerships with larger pharmaceutical firms for joint development and marketing of its drug candidates, which can provide additional income through upfront payments and royalties on sales. Research grants and funding from government and private entities for clinical trials and product development may also contribute to its revenue. Additionally, licensing agreements for its intellectual property could serve as significant revenue streams, enhancing the company's financial stability.

NewAmsterdam Pharma Company Financial Statement Overview

Summary

NewAmsterdam Pharma Company exhibits typical characteristics of a biotech firm with high R&D expenses leading to operational losses. While revenue growth is promising, profitability remains a challenge. The balance sheet is strong with low leverage, providing stability. Cash flows are negative, but capital raising efforts support liquidity. The company must focus on achieving profitability to ensure long-term sustainability.

Income Statement

The company's revenue has shown significant volatility with periods of growth and decline. The gross profit margin is 100% due to no cost of goods sold, but the net profit margin is low due to high operating expenses. EBIT and EBITDA margins are negative, indicating operational challenges. Revenue growth from 2023 to 2024 is strong, but the company has not achieved profitability.

Balance Sheet

The company maintains a strong equity position with an equity ratio of 87.6%, indicating low leverage. Debt-to-equity is minimal at 0.06, suggesting low financial risk. However, the company has reported consecutive net losses, impacting return on equity, which remains negative.

Cash Flow

Operating cash flow is consistently negative, highlighting cash burn issues typical in the biotechnology industry. Free cash flow growth is negative, indicating increased outflows. However, ample financing cash flow suggests the company is able to raise capital successfully, mitigating immediate liquidity concerns.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	35.24M	45.56M	14.09M	102.69M	0.00	0.00
Gross Profit	35.24M	45.56M	14.09M	102.69M	0.00	0.00
EBITDA	-288.10M	-241.49M	-176.86M	-22.34M	-41.37M	-6.63M
Net Income	-221.07M	-241.60M	-176.94M	-22.63M	-41.78M	-7.02M
Balance Sheet
Total Assets	786.43M	864.62M	347.10M	478.50M	67.99M	139.87M
Cash, Cash Equivalents and Short-Term Investments	702.95M	834.19M	340.45M	467.73M	60.38M	1.37M
Total Debt	266.00K	448.00K	60.00K	126.00K	186.51K	0.00
Total Liabilities	58.36M	107.12M	58.70M	48.43M	11.36M	12.41M
Stockholders Equity	728.07M	757.50M	288.39M	430.07M	56.63M	127.46M
Cash Flow
Free Cash Flow	-144.54M	-159.24M	-141.24M	10.44M	-29.54M	―
Operating Cash Flow	-144.39M	-158.56M	-141.22M	10.66M	-29.51M	―
Investing Cash Flow	-215.95M	-62.85M	-24.00K	-221.00K	-24.00K	―
Financing Cash Flow	472.45M	659.51M	8.91M	391.90M	84.70M	13.92M

NewAmsterdam Pharma Company Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 38.33
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NAMS, the sentiment is Negative. The current price of 38.33 is below the 20-day moving average (MA) of 38.60, above the 50-day MA of 35.91, and above the 200-day MA of 24.79, indicating a neutral trend. The MACD of 0.78 indicates Positive momentum. The RSI at 42.37 is Neutral, neither overbought nor oversold. The STOCH value of 33.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NAMS.

NewAmsterdam Pharma Company Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KNSA	72 Outperform	$3.04B	89.36	7.39%	―	55.68%	―
NAMS	58 Neutral	$4.35B	-17.40	-39.94%	―	―	―
VKTX	53 Neutral	$3.91B	―	-29.23%	―	―	-126.16%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
XENE	48 Neutral	$3.31B	―	-45.14%	―	―	-38.30%
IMVT	45 Neutral	$3.99B	―	-95.93%	―	―	-27.70%
SLNO	37 Underperform	$2.58B	―	-20.66%	―	―	44.84%

NewAmsterdam Pharma Company Corporate Events

NewAmsterdam Pharma Reports Q3 2025 Financial Results

NewAmsterdam Pharma Company N.V. is a late-stage biopharmaceutical company based in the Netherlands, focusing on developing therapies for cardiometabolic diseases, particularly those involving cholesterol management. The company recently released its earnings report for the third quarter of 2025, highlighting its ongoing efforts in the development of its lead product candidate, obicetrapib, a CETP inhibitor aimed at lowering LDL cholesterol levels. Despite a net loss of $72 million for the quarter, NewAmsterdam Pharma reported revenues of $348,000, primarily from supply agreements, and continued to invest heavily in research and development, with expenses reaching $31 million. The company also noted a decrease in cash and cash equivalents from $771 million at the end of 2024 to $539 million by September 2025, reflecting its significant investment in product development and operational activities. Looking forward, NewAmsterdam Pharma remains committed to advancing its clinical trials and exploring new market opportunities for obicetrapib, with management expressing optimism about the potential for regulatory approvals and future revenue growth.

NewAmsterdam Pharma Achieves Key EMA Regulatory Milestone

On November 5, 2025, NewAmsterdam Pharma announced its third-quarter financial results and provided a corporate update. The company reported a significant regulatory milestone with the European Medicines Agency’s acceptance of marketing authorization applications for obicetrapib and its fixed-dose combination with ezetimibe. Despite a decrease in revenue and an increase in net loss compared to the previous year, NewAmsterdam continues to advance its clinical development strategy and build global infrastructure to support the potential launch of obicetrapib. The company also highlighted its ongoing trials and upcoming milestones, emphasizing its commitment to providing a differentiated therapy in the cardiovascular market.

The most recent analyst rating on (NAMS) stock is a Hold with a $36.00 price target. To see the full list of analyst forecasts on NewAmsterdam Pharma Company stock, see the NAMS Stock Forecast page.

NewAmsterdam Pharma’s Latest Study: A Game Changer for Metabolic Disorders?

Study Overview: NewAmsterdam Pharma is conducting a Phase 3 study, officially titled A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib 10 mg and Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome (RUBENS Trial). The study aims to assess the efficacy, safety, and tolerability of obicetrapib, both as a fixed-dose combination with ezetimibe and as monotherapy, in patients with metabolic syndrome and/or Type 2 Diabetes Mellitus.

NewAmsterdam Pharma’s Antioxidant Study: A Potential Game Changer?

NewAmsterdam Pharma Company N.V. is conducting a clinical study titled ‘A Randomized, Double-Blind, Placebo-Controlled Parallel Trial to Assess the Effects of Obicetrapib on Levels of Antioxidants in Plasma and HDL Particles in Healthy Volunteers: The VERMEER Study.’ The study aims to evaluate whether Obicetrapib can enhance antioxidant absorption in blood and eye tissue, potentially offering a novel approach to improving antioxidant levels in the body.

NewAmsterdam Pharma’s VINCENT Study: A Promising Step in Cardiovascular Treatment

Study Overview: NewAmsterdam Pharma is conducting a Phase 2 clinical trial titled A Phase 2 Study to Evaluate the Effect of Obicetrapib Alone and in Combination With Evolocumab (Repatha®) on Lipoprotein (a) in Patients With Mild Dyslipidemia: The VINCENT Study. The study aims to assess the impact of obicetrapib, both alone and in combination with evolocumab, on lowering Lp(a) levels in patients with mild dyslipidemia, a condition linked to cardiovascular risk.

NewAmsterdam Pharma’s REMBRANDT Trial: A Potential Game-Changer in Cardiovascular Treatment

NewAmsterdam Pharma Company N.V. (NAMS) is conducting a Phase 3 study titled A Placebo-controlled, Double-blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib/Ezetimibe Fixed Dose Combination Daily on Coronary Plaque Characteristics in Participants With Atherosclerotic Cardiovascular Disease on Coronary CT Angiography (REMBRANDT Trial). The study aims to assess the impact of a fixed-dose combination of obicetrapib and ezetimibe on coronary plaque and inflammation in patients with high-risk atherosclerotic cardiovascular disease (ASCVD) who are not adequately controlled by their current lipid-modifying therapy.

NewAmsterdam Pharma Highlights Progress in Obicetrapib Trials

On September 2, 2025, NewAmsterdam Pharma Company released an updated corporate investor presentation highlighting significant progress in its clinical trials for obicetrapib, a promising treatment for lowering LDL-C levels. The presentation detailed the company’s strategic plans, including securing funding for a potential U.S. commercial launch and expanding its workforce. The company’s trials have shown favorable results, indicating a substantial market opportunity, particularly in the U.S., where many patients are not meeting cholesterol goals with existing treatments.

The most recent analyst rating on (NAMS) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on NewAmsterdam Pharma Company stock, see the NAMS Stock Forecast page.

NewAmsterdam Pharma’s EMA Validation for Obicetrapib

On August 18, 2025, NewAmsterdam Pharma announced that the European Medicines Agency has validated the Marketing Authorization Application for obicetrapib, both as a monotherapy and in combination with ezetimibe, for treating primary hypercholesterolemia and mixed dyslipidemia. This validation marks a significant step for NewAmsterdam, allowing the EMA to review pivotal Phase 3 trials, which demonstrated substantial LDL-C reductions. The company, in partnership with Menarini, aims to bring this novel treatment to Europe, potentially offering a new therapeutic option for patients not meeting LDL-C goals despite existing treatments.

The most recent analyst rating on (NAMS) stock is a Hold with a $23.60 price target. To see the full list of analyst forecasts on NewAmsterdam Pharma Company stock, see the NAMS Stock Forecast page.

NewAmsterdam Pharma Signs Supply Agreement with Menarini

On August 12, 2025, NewAmsterdam Pharma’s subsidiary entered into a Supply Agreement with A. Menarini International Licensing S.A. to supply obicetrapib monotherapy and combination drug products. The agreement outlines NewAmsterdam Pharma as the exclusive supplier initially, with plans to transfer manufacturing to Menarini or a third party, impacting the company’s operational dynamics and industry positioning.

The most recent analyst rating on (NAMS) stock is a Hold with a $23.60 price target. To see the full list of analyst forecasts on NewAmsterdam Pharma Company stock, see the NAMS Stock Forecast page.